Continue to Site

Biogen unveils FTC aducanumab probe

By Brian Buntz | February 4, 2022

In its annual SEC report, Biogen reported that the Federal Trade Commission had sent the company a civil investigative demand related to the controversial Alzheimer’s drug aducanumab (Aduhelm).

The company received a similar notice from the SEC.

Lawmakers in the U.S. House of Representatives and the Office of Inspector General of HHS are also investigating the approval and marketing of the drug.

The House Committee on Oversight and Reform had balked at Biogen’s initial plan to price the drug at $56,000 for a patient with an average weight. However, the company later cut the cost by approximately half.

Aducanumab exemplifies one of the most troubled drug rollouts in recent memory.

CMS has proposed drastically limiting coverage of aducanumab and other future drugs until more convincing efficacy data are available.

Aduhelm generated approximately $3 million in revenue in 2021.

Filed Under: Neurological Disease
Tagged With: Aducanumab, Biogen

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.